Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Takeda, Pharmacia Tie Up for Marketing of OTC NRT Products
May 28, 2001
- International A-II Symposium 2001 Held by Banyu
May 28, 2001
- DIAGNOSTIC NEWS IN BRIEF -1-
May 28, 2001
- Meiji Seika, Solvay to Codevelop Drug for Parkinson's Disease
May 28, 2001
- Sun Drug: Sales, Profits Show Double-Digit Increases
May 28, 2001
- DIAGNOSTIC NEWS IN BRIEF -2-
May 28, 2001
- Current Status of Antibody Drug Development Reported: PMSRL Seminar
May 28, 2001
- ABBREVIATION OF THE WEEK
May 28, 2001
- BUSINESS NEWS IN BRIEF -1-
May 28, 2001
- Terumo: Consolidated Sales Increase for 7 Consecutive Years to \176 Bil.
May 28, 2001
- BUSINESS NEWS IN BRIEF -2-
May 28, 2001
- NEDO to Develop Gene Diagnosis System for Cancer, Therapeutic Systems for Cardiac Disease
May 28, 2001
- CDFS Recommends 7 Ingredients Including Montelukast, Zolmitriptan for Approval
May 28, 2001
- Protecting, Fostering Innovation Must Be Fundamental Part of Healthcare System: Dr McKinnell of PhRMA
May 28, 2001
- BUSINESS NEWS IN BRIEF -3-
May 28, 2001
- 5 of 7 Firms Including Takeda, Eisai, Daiichi Report Record-high Profits
May 28, 2001
- Classification of Existing Drugs Proposed at Chuikyo
May 28, 2001
- Mitsubishi-Tokyo: Sales Total \84.2 Bil.,Attributable to Growth of Mainstays
May 28, 2001
- Industry Opposes Ministry Data on Prices of Original Products and Generics
May 28, 2001
- Mitsubishi Chemical: Pharmaceutical Sales Top \127.4 Bil.
May 28, 2001
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…